Ariad Pharmaceuticals Incorporated - Price Analysis Snapshot

This Report features up to a ten-year record of the equity Price history for Ariad Pharmaceuticals Incorporated. Tabular results include the High, Low and Closing price for the quarter. There is also a calculation of percentage change in price for both Quarterly and Annual periods. Price values are adjusted for stock splits and dividends.

Ariad Pharmaceuticals Incorporated. The Group's principal activities are the discovery and development of medicines that treat cancer by regulating cell signaling with small molecules. The Group's lead product candidate, AP23573, is in multiple Phase 1 and Phase 2 clinical trials and is used for the treatment of solid tumors and hematologic cancers. In the Group's bone-targeted mTOR inhibitor program, it is developing a novel and potent follow-on product candidate analogous to AP23573, which treats bone cancers and block the spread of bone sarcomas. In the Group's oncogenic kinase inhibitor program, it is developing potent inhibitors of enzymes involved in the growth, proliferation and spread of cancer. The Group operates in the United States.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report